December 2020 FDA Recall Ketorolac Tromethamine by Fresenius Kabi Usa, Llc
D-0245-2021 - Presence of Particulate Matter - found in reserve sample vials at the firm.

This Class I drug recall was voluntarily initiated by Fresenius Kabi Usa, Llc on December 23, 2020 for the product Ketorolac Tromethamine. The FDA reported the reason for recall as presence of particulate matter - found in reserve sample vials at the firm.. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0245-2021

Reason for Recall
Presence of Particulate Matter - found in reserve sample vials at the firm.
Initiated
12-23-2020
Reported
02-03-2021
Quantity
945,425 vials

Recall Profile & Regulatory Data

Class I - is a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.
Fresenius Kabi USA, LLC
Nationwide USA and Puerto Rico
Ketorolac Tromethamine Injection, USP, 30 mg per mL, packaged in 1 mL Single Dose Vials (NDC 63323-162-00); 25 x 1 mL Single Dose Vials per tray (NDC 63323-162-01); For IM or IV use, Rx only, Fresenius Kabi, Lake Zurich, IL 60047.

Batch or Lot Expiration Information

Lot# 6121083, Exp 2/2021